Fig. 2
miR-128-3p expression in CRC cell lines and its effect on oxaliplatin resistance. a RT-qPCR assay was performed to detect the miR-128-3p expression in parent and resistant CRC cells. b RT-qPCR assay was performed to detect the miR-128-3p expression in HCT116OxR cells transfected with lenti-miR-128-3p (Lv-128) and lenti-negative control (Ctrl). c CCK8 assay of HCT116OxR cells transfected with Lv-128 and Ctrl with oxaliplatin treatment at indicated concentrations. d Flow cytometry for apoptosis assay of HCT116OxR cells transfected with Lv-128 and Ctrl with oxaliplatin treatment (30 μM). e Western blot analysis of E-cad, N-cad, Vim, and Fn expression in HCT116OxR cells transfected with Lv-128 and Ctrl. f Migration and invasion ability of HCT116OxR cells transfected with Lv-128 and Ctrl were assessed by Transwell assay. g Motility ability of HCT116OxR cells transfected with Lv-128 and Ctrl were assessed by wound healing assays. h Accumulation of Pt in HCT116OxR cells transfected with Lv-128 and Ctrl following exposure to 30 μM, 24 h oxaliplatin treatment. i Total Pt-DNA adduct levels in HCT116OxR cells transfected with Lv-128 and Ctrl following exposure to 30 μM, 24 h oxaliplatin treatment. j The immunofluorescence analysis of nuclear foci for γ-H2AX expression in HCT116OxR cells transfected with Lv-128 or Ctrl after 24 h oxaliplatin exposure (30 μM). Scale bars, 10 μm. Subcutaneous xenograft assay of miR-128-3p-overexpressing and control HCT116OxR cells (5 × 106 cells) in nude mice with vehicle (veh) or oxaliplatin (Oxa, 90 mg/m2) treatment. Tumor volume of xenograft models were measured from day 0 to day 42. Volumes of tumors (k) and representative bioluminescent images (l) are shown (n = 5). Results are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001